PLIANT THERAPEUTICS INC (PLRX)
US7291391057 - Common Stock
PLRX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. While PLRX seems to be doing ok healthwise, there are quite some concerns on its profitability. PLRX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PLRX had negative earnings in the past year.
PLRX had a negative operating cash flow in the past year.
PLRX had negative earnings in each of the past 5 years.
In the past 5 years PLRX always reported negative operating cash flow.
1.2 Ratios
PLRX has a Return On Assets of -31.50%. This is comparable to the rest of the industry: PLRX outperforms 55.90% of its industry peers.
PLRX's Return On Equity of -34.07% is fine compared to the rest of the industry. PLRX outperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.5% | ||
| ROE | -34.07% | ||
| ROIC | N/A |
ROA(3y)-36.88%
ROA(5y)-26.09%
ROE(3y)-40.76%
ROE(5y)-28.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PLRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PLRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
PLRX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PLRX has been increased compared to 5 years ago.
Compared to 1 year ago, PLRX has an improved debt to assets ratio.
2.2 Solvency
PLRX has an Altman-Z score of 10.43. This indicates that PLRX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 10.43, PLRX belongs to the best of the industry, outperforming 87.69% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that PLRX is not too dependend on debt financing.
PLRX has a Debt to Equity ratio (0.02) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 10.43 |
ROIC/WACCN/A
WACC9.27%
2.3 Liquidity
A Current Ratio of 17.72 indicates that PLRX has no problem at all paying its short term obligations.
The Current ratio of PLRX (17.72) is better than 92.82% of its industry peers.
A Quick Ratio of 17.72 indicates that PLRX has no problem at all paying its short term obligations.
PLRX has a better Quick ratio (17.72) than 92.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.72 | ||
| Quick Ratio | 17.72 |
3. Growth
3.1 Past
PLRX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.07%.
PLRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -83.69%.
The Revenue for PLRX have been decreasing by -66.44% on average. This is quite bad
EPS 1Y (TTM)7.07%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q4.17%
Revenue 1Y (TTM)-83.69%
Revenue growth 3Y-66.44%
Revenue growth 5YN/A
Revenue growth Q2Q-100%
3.2 Future
PLRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.60% yearly.
The Revenue is expected to grow by 177.67% on average over the next years. This is a very strong growth
EPS Next Y-21.34%
EPS Next 2Y-13.27%
EPS Next 3Y-12.39%
EPS Next 5Y9.6%
Revenue Next Year-61.05%
Revenue Next 2Y29.71%
Revenue Next 3Y39.37%
Revenue Next 5Y177.67%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PLRX. In the last year negative earnings were reported.
Also next year PLRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PLRX's earnings are expected to decrease with -12.39% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.27%
EPS Next 3Y-12.39%
5. Dividend
5.1 Amount
PLRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PLIANT THERAPEUTICS INC
NASDAQ:PLRX (5/2/2024, 7:13:39 PM)
After market: 13.25 0 (0%)13.25
+0.59 (+4.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap798.18M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -31.5% | ||
| ROE | -34.07% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 17.72 | ||
| Quick Ratio | 17.72 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)7.07%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-21.34%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-83.69%
Revenue growth 3Y-66.44%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y